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Case ReportCentral Nervous System Involvement in
Cutaneous T-Cell Lymphoma: 2 Illustrative
Cases and a Review of Current Literature
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 Cutaneous T-cell lymphoma (CTCL) is a subtype of
lymphoma. Involvement of the central nervous system
(CNS) is a rare complication and is reportedly asso-
ciated with poor prognosis.
 CNS involvement in CTCL manifests as parenchymal
or leptomeningeal metastases.
 Awareness of potential CNS involvement in CTCL is
critical in recognizing or identifying the disease and
initiating CNS-directed treatment.Clinical Lymphoma, Myeloma & Leukemia, Vol. 14, No. 1, e25-30 ª 2014 The Authors. Published by Elsevier Inc.
Keywords: Chemotherapy, Diagnosis, Prognosis, PTCL, Treatment
Open access under CC BY-NC-SA license.Cases and Introduction
Case 1
A 64-year-old woman with longstanding facial and body
eczematous dermatitis presented with large ulcerating masses on the
neck and right upper eyelid as well as multiple erythematous scaly
plaques on the trunk and extremities (Fig. 1A). Skin biopsy and
T-cell receptor (TCR) gene rearrangement studies were consistent
with cutaneous T-cell lymphoma (CTCL), mycosis fungoides
(MF) type (CTCL/MF). Dermatopathology showed psoriasiform
dermatitis with an epidermotropic T-cell inﬁltrate with enlarged
and hyperchromatic nuclei. Flow cytometry revealed that the
atypical T cells were CD3 positive (CD3þ) and CD4þ, with loss of
CD8, CD5, and CD7 positivity and only rare CD30 positivity. A
clonal TCR gamma chain gene rearrangement was found by PCR.
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Open access under CC BY-NC-SA latypical lymphocytes. During the patient’s evaluation, the tumor
over the right orbit rapidly enlarged and ulcerated (see Fig. 1B).
She developed neurologic symptoms including a subtle left
hemiparesis, left-sided limb ataxia, mild intention tremor, and
difﬁculty with cognition and word ﬁnding. Magnetic resonance
imaging (MRI) of the brain showed minimal contrast enhance-
ment; however, the ﬂuid attenuated inversion recovery (FLAIR)
sequence revealed a large right hemispheric signal abnormality in
the right centrum semiovale (Fig. 2A, B). Cerebrospinal ﬂuid
(CSF) cytology and ﬂow cytometry were negative for infection or
tumor. Brain biopsy was recommended to the patient, but she
declined. Based on the clinical scenario, the cancer was staged as
IVB CTCL/MF with parenchymal central nervous system (CNS)
involvement. The patient underwent electron beam radiation
therapy with a cumulative dose of 36 Gy to her cutaneous tumors,
with signiﬁcant shrinkage of these masses (see Fig. 1C, D). After
the development of neurologic signs and symptoms, she was treated
with oral dexamethasone and high-dose intravenous methotrexate
(HD-MTX) (8 g/m2). She completed 8 cycles of HD-MTX (4
cycles administered once every 2 weeks and subsequently 4 cycles
once every 4 weeks) with complete resolution of neurologic
symptoms and normalization of brain MRI changes (see Fig. 2C,
D). The patient’s patch-stage skin lesions initially improved with
HD-MTX but slowly recurred off therapy. Maintenance chemo-
therapy with oral bexarotene was started, which was changed
to intravenous romidepsin therapy after she developed additional
cutaneous tumors. One year after her initial presentation, theClinical Lymphoma, Myeloma & Leukemia February 2014 - e25icense.
Figure 1 Initial Clinical Presentation of Plaques and Tumors on the Neck (A) and the Right Eyelid (B), and Responses to Electron Beam
Irradiation in 4 Months (C and D)
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e26 -patient is fully functional in her daily activities, with a normal
neurologic examination, and has stable cutaneous disease.
Follow-up brain MRI found no evidence of recurrent or residual
metastasis.
Case 2
A 52-year-old man with a medical history including coronary
artery disease, chronic obstructive pulmonary disease, and type 2
diabetes mellitus presented with intermittent, progressive, painful
erythematous papules and plaques on the upper chest and upper
extremities over 2 years (Fig. 3A). Concurrent with the skin
eruption, he developed episodic but progressive weakness ulti-
mately resulting in C5 asymmetric tetraplegia that necessitated the
use of a motorized wheelchair. Before presentation at the authors’
institution, he had been treated with multiple courses of high-dose
pulse intravenous methylprednisolone for presumed idiopathic
transverse myelitis, with temporary improvement of skin lesions
and leg weakness after each treatment course. Subsequently a skin
biopsy found an atypical dermal lymphoid inﬁltrate with an
abnormal immunophenotype revealing a CD3þ, CD4þ T-cell
inﬁltrate with decreased expression of CD2 and CD7. CD25,
CD30, and CD56 were negative. TCR gene rearrangement
studies conﬁrmed the presence of a T-cell clone. Brain MRI
showed patchy small-volume bihemispheric parenchymal lesions
in the supratentorial and infratentorial compartments. Spine MRI
found extensive cervical and lumbar leptomeningeal and paren-
chymal enhancement and associated subarachnoid nodules (see
Fig. 3B, C, D). CSF analysis found elevated glucose and protein,
with the presence of atypical lymphocytes. CSF ﬂow cytometry
conﬁrmed an abnormal T-cell population with an immunophe-
notype similar to that of the skin, with a low level also detected in
the peripheral blood. Based on the presence of the same TCR
clone in the skin, CSF, and blood, the patient was diagnosed withClinical Lymphoma, Myeloma & Leukemia February 2014CTCL (peripheral T-cell lymphoma, not otherwise speciﬁed) with
brain and spine parenchymal and leptomeningeal involvement.
The patient was treated with pulse-dose intravenous methyl-
prednisolone and intravenous immunoglobulin, followed by HD-
MTX, 8 g/m2, for 6 cycles (each cycle administered every 2
weeks). Repeat MRI imaging showed minimal response in the
brain and spine, although his neurologic examination remained
stable. He was subsequently started on pemetrexed, 500 mg/m2,
administered once every 3 weeks, a therapy administered on an
outpatient basis. Six months after diagnosis of CTCL and with
continued pemetrexed treatment, the patient remains neurologi-
cally stable with a modest clinical response and stable neuro-
radiographic disease.
Discussion
CTCL is a subtype of non-Hodgkin lymphoma with protean
clinical manifestations and an estimated incidence of 1 case per
100,000 person-years.1 MF, CD30þ primary lymphoproliferative
disease, and Sézary syndrome are the most common subtypes of
CTCL, with MF comprising the majority (> 60%) of cases of
CTCL. Current World Health Organization (WHO)/European
Organisation for Research and Treatment of Cancer (EORTC)
classiﬁcation divides the remaining subtypes of CTCL based
on differing biologic and clinical characteristics; they include
(among others) adult T-cell leukemia/lymphoma, subcutaneous
panniculitis-like T-cell lymphoma, extranodal natural killer (NK)/
T-cell lymphoma (nasal type), and peripheral T-cell lymphoma,
unspeciﬁed (PTCL), an entity that encompasses several provisional
diseases (primary cutaneous g/d T-cell lymphoma, primary cuta-
neous aggressive epidermotropic CD8þ cytotoxic T-cell lymphoma,
and primary cutaneous small/medium CD4þ T-cell lymphoma).
CTCL may be indolent or aggressive, with long-term survival rates
ranging from 100% in stage T1 MF to 40% in stage T3 or T4 MF.2
Figure 2 (A) MRI of the Brain, Axial FLAIR Sequence Pretreatment Study, Demonstrating High Signal Intensity in the Right Deep
Periventricular White Matter With Associated Mass Effect. (B) MRI of the Brain, T1 Postcontrast Axial Sequence Pretreatment
Study, Showing Speckled Enhancement in the Right Periventricular White Matter, Striatum, and Internal Capsule. (C, D) MRI
of the Brain, Axial FLAIR (C) and Axial T1 Postcontrast (D) Sequences Posttreatment, Showing No Abnormal Signal (ie, a
Normal Study)
Abbreviations: FLAIR ¼ ﬂuid attenuated inversion recovery; MRI ¼ magnetic resonance imaging.
Ge Zhao et alThe prognosis of PTCL, in general, is poor, with a 5-year survival
rate < 20%.3
Extracutaneous involvement in CTCL is rare in patients with
limited patch- or plaque-stage disease, although it is more
commonly seen in patients with tumor-stage disease or eryth-
roderma. The most frequently involved extracutaneous sites are
regional lymph nodes, visceral organs, and bone marrow. CNS
manifestations in CTCL are rare. A retrospective analysis found that
the overall incidence of direct neurologic complications in CTCL
was 4%.4 CNS involvement in MF was the least common, with
only 1.3% to 1.5% of patients having neurologic involvement.4,5
PTCL has the highest CNS metastases rate, ranging from 8.5%
to 10%.5,6
At present, there are approximately 80 cases of CTCL with CNS
involvement reported in the literature, with the majority presentedas case reports.4-14 The clinical features that were presented in
several of the large case series of CTCL with CNS involvement
are summarized in Table 1. Most studies have noted CNS
involvement in patients with MF, presumably because MF is much
more common than other subtypes of CTCL. The estimated clin-
ical incidence of CNS involvement in CTCL is lower than that
found in autopsy studies, with a large autopsy series estimating
the incidence of CNS involvement in MF to be 14%.7 This clini-
copathologic discrepancy suggests that CNS involvement in CTCL,
at least in the MF type, may be insidious, without overt clinical
symptoms.
Most cases of MF with CNS involvement have been in older men
with an average age of 65 years and with associated visceral organ
involvement and advanced skin disease.4 MF patients with large-cell
transformation are at particularly increased risk of CNSClinical Lymphoma, Myeloma & Leukemia February 2014 - e27
Figure 3 (A) Clinical Presentation of Erythematous Papules and Plaques on the Upper Chest. (B) MRI of the Brain, T1 Postcontrast
Axial Sequence, Demonstrating Punctate Contrast Enhancement in the Right Posterior Limb of the Internal Capsule. (C) MRI
of the Cervical Spine, Sagittal T1 Postcontrast Sequence, Showing Intramedullary and Leptomeningeal Enhancement With
Extension Into the Thoracic Spine. (D) MRI of the Lumbar Spine, Sagittal T1 Postcontrast Sequence, Demonstrating Nodular
Enhancement of the Cauda Equina
Abbreviation: MRI ¼ magnetic resonance imaging.
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e28 -involvement.7 The average interval between diagnosis of MF and
development of CNS symptoms was < 3 years in one case series,4
whereas patients with CNS disease in PTCL tend to present more
rapidly, with an average interval of onset of 9 months.6 Notably,
CNS involvement may occur when skin disease is well controlled or
in remission, and neurologic symptoms can develop at any stage of
disease.7 The most common neurologic symptoms reported are
altered mental status, cranial neuropathies, and speech difﬁculties.
Other neurologic symptoms may include headache, fatigue, cogni-
tive change, gait disturbance, or seizure.
CNS involvement in CTCL can manifest as parenchymal
metastases, leptomeningeal metastases, or both. Brain biopsy is the
gold standard to conﬁrm CNS disease, and conﬁrmation of lep-
tomeningeal involvement requires demonstration of atypical
malignant T-cells in the CSF. In practice, brain biopsy is seldom
performed. In the cases series and case reports of CNS involvementClinical Lymphoma, Myeloma & Leukemia February 2014in CTCL,4-14 only 3 of 50 cases were conﬁrmed with brain biopsy.
Nine were conﬁrmed by autopsy, and the remaining diagnoses were
based on the clinical scenario combined with CSF studies and
computed tomography (CT) or MRI ﬁndings. The International
Society for Cutaneous Lymphomas (ISCL) and EORTC do not
speciﬁcally address CNS involvement in the most recent staging
guidelines, but they do recommend pathologic conﬁrmation of
any suspected visceral lesion outside of splenomegaly.15 Some
researchers have suggested that elevated b2-microglobulin and
lactate dehydrogenase levels may be markers of CNS involve-
ment.4,6,16 However, the use of these biomarkers remains contro-
versial, and their signiﬁcance as predicators of CNS involvement has
not been conﬁrmed.7
There are no standard guidelines regarding routine diagnostic
evaluation for CNS involvement in CTCL, nor is there guidance
regarding the use of CNS prophylactic treatment. Vu and Duvic7
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Ge Zhao et alrecommended annual screening of patients with transformed MF
for CNS disease with head CT and orbital cuts. Stein et al4 propose
prophylactic whole brain irradiation or alternatively intra-CSF
chemotherapy in patients with MF and risk factors, as suggested
for other aggressive non-Hodgkin lymphomas at risk for CNS
metastases. Given the low numbers of cases of CNS metastases in
CTCL, the efﬁcacy of these recommendations is understandably
difﬁcult to quantitate for the general CTCL population, and such
treatments should currently be applied only in special circum-
stances. Careful review of the history and physical examination
(including attention to subtle neurologic symptoms or an early
referral to a neurologist) and collaboration with multispecialty on-
cologists are important for the early diagnosis and management of
CTCL with CNS involvement.
The patient described in case 1 declined brain biopsy. Although a
differential diagnosis of cerebrovascular events, infection, other
brain malignancy, or other metastatic cancers could have been
considered, the negative CSF evaluation for other possible entities,
the clinical scenario, and the response to treatment suggested CNS
involvement by MF. Without a tissue diagnosis, it was not possible
to differentiate MF-related CNS metastasis from primary CNS
lymphoma. There is a single case report of a patient with a history
of MF who developed multifocal epithelioid glioblastoma that
mimicked metastatic T-cell lymphoma,17 although such disease is
exceedingly rare and would not be expected to respond to
HD-MTX, as seen in the authors’ patient.
The prognosis of CNS involvement in CTCL is poor, and the
majority of the patients die within 6 months after the diagnosis of
CNS involvement. A delay in the diagnosis and treatment of CNS
involvement of CTCL may partly contribute to the short survival
time previously reported. There is a single case report of a young
patient with CNS involvement of CTCL and prolonged survival
after autologous stem cell transplantation.18 Owing to the low
incidence of CNS metastases, there are limited data evaluating or
comparing different treatment regimens. Empiric treatment options
include whole brain radiation therapy, intra-CSF chemotherapy,
and systemic chemotherapy. Surgical resection and autologous stem
cell transplantation have also been reported. Some studies have
suggested that more aggressive treatment, such as the combination
of brain irradiation, chemotherapy, and autologous stem cell
transplantation, may be associated with better outcomes,6,7,18
although the number of such cases is currently too small to sup-
port this treatment recommendation.
Conclusion
In summary, CNS involvement in CTCL is a rare metastatic
manifestation with a generally poor prognosis. Awareness of subtle
neurologic symptoms, even in patients with well-controlled skin
disease, is critical in identifying underlying CNS involvement.
Diagnosis relies on a combination of clinical presentation, neuro-
imaging, CSF evaluation, and, when feasible, CNS biopsy. There is
no consensus regarding standard treatment of CNS metastases,
although more aggressive and timely treatment may be associated
with better clinical outcomes.
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